Harnessing prazosin for tumors: Liposome hybrid nanovesicles activate tumor immunotherapy via autophagy inhibition
Source abstract
Abstract
Prazosin (Prz), an antagonist of alpha-1 adrenergic receptors, is conventionally employed in the treatment of hypertension. Our study pioneers the exploration of Prz in oncology, examining its impact on cellular autophagy and its potential to trigger antitumor immune responses. We have developed a novel Prz-loaded liposome hybrid nanovesicle (Prz@LINV) system, integrating tumor-derived nanovesicles (TNV) with liposomes (LIP) to facilitate targeted Prz delivery to tumor sites. This formulation enhances Prz bioavailability and markedly inhibits tumor cell autophagy, leading to immunogenic cell death (ICD) and the activation of antitumor immune responses. Furthermore, Prz@LINV modulates dendritic cells (DCs), augmenting their antigen cross-presentation capacity and thereby potentiating antitumor immunity. These effects were validated in a colorectal cancer mouse model, demonstrating the good biocompatibility of Prz@LINV and its significant inhibition in tumor growth, along with the enhancement of antitumor immune responses. Our findings elucidate a novel mechanism by which Prz inhibits autophagy and enhances the antitumor immune response, providing a foundation for the development of innovative immunotherapeutic strategies. The efficacy of Prz@LINV suggests that Prz may emerge as a pivotal component in future immunotherapeutic regimens, offering patients more potent therapeutic options.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Autophagy in Disease and Therapy · Adenosine and Purinergic Signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Cancer statistics10.3322/caac.21820 ↗
2. Cancer incidence and mortality in China, 202210.1016/j.jncc.2024.01.006 ↗
3. Overcoming cancer therapeutic bottleneck by drug repurposing10.1038/s41392-020-00213-8 ↗
4. Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle10.1593/neo.07475 ↗
5. Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment10.18632/oncotarget.28010 ↗
6. Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension10.1001/jama.1977.03270370061024 ↗
7. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia10.1046/j.1442-2042.2000.00175.x ↗
8. Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel
9. Small molecule enhancers of endosome-to-cytosol import augment anti-tumor immunity10.1016/j.celrep.2020.107905 ↗
10. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway10.15252/emmm.201505421 ↗
11. The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells10.1007/s00277-009-0704-z ↗
12. The cytotoxic effects of prazosin, chlorpromazine, and haloperidol on hepatocellular carcinoma and immortalized non-tumor liver cells, Medical oncology10.1007/s12032-024-02323-7 ↗
13. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway10.1158/0008-5472.CAN-05-2039 ↗
14. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis10.1002/pros.20260 ↗
15. Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase10.1007/s00240-003-0365-7 ↗
16. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth10.1016/j.ccell.2023.02.016 ↗
17. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation10.1038/s41418-019-0297-6 ↗
18. Prazosin induced lysosomal tubulation interferes with cytokinesis and the endocytic sorting of the tumour antigen CD98hc, Biochimica et biophysica acta
19. Gold nanoparticle-directed autophagy intervention for antitumor immunotherapy via inhibiting tumor-associated macrophage M2 polarization10.1016/j.apsb.2022.02.008 ↗
20. ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape
21. Autophagy-modulating biomembrane nanostructures: a robust anticancer weapon by modulating the inner and outer cancer environment10.1016/j.jconrel.2023.12.032 ↗
22. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy10.1021/acsnano.0c09681 ↗
23. Efficient immunogenic peptide antigen delivery to dendritic cells using an ESCRT-mediated extracellular vesicle formation method10.1016/j.vaccine.2021.04.021 ↗
24. OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy10.1016/j.jconrel.2023.11.051 ↗
25. Lipid-hybrid cell-derived biomimetic functional materials: a state-of-the-art multifunctional weapon against tumors, Materials today
26. Drug nanocrystallisation within liposomes10.1016/j.jconrel.2018.09.001 ↗
27. The alpha-adrenergic antagonist prazosin promotes cytosolic siRNA delivery from lysosomal compartments10.1016/j.jconrel.2023.10.014 ↗
28. Doxil®--the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
29. Liposomes characterization for market approval as pharmaceutical products: analytical methods, guidelines and standardized protocols10.1016/j.jpba.2023.115751 ↗
30. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity10.1517/17425247.2011.566552 ↗
31. An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota10.1016/j.apsb.2024.03.014 ↗
32. Targeted sonodynamic therapy platform for holistic integrative Helicobacter pylori therapy
33. A dendritic cell-recruiting, antimicrobial blood clot hydrogel for melanoma recurrence prevention and infected wound management10.1016/j.biomaterials.2024.122776 ↗
34. Treatment with mesenchymal stem cell-derived nanovesicle-containing gelatin methacryloyl hydrogels alleviates osteoarthritis by modulating chondrogenesis and macrophage polarization
35. Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles10.1002/advs.202103745 ↗
36. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment10.7150/thno.37198 ↗
37. EXOPLEXs: chimeric drug delivery platform from the fusion of cell-derived nanovesicles and liposomes10.1021/acs.biomac.7b01176 ↗
38. Adaptive design of nanovesicles overcoming immunotherapeutic limitations of chemotherapeutic drugs through poliovirus receptor blockade
39. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery10.1021/nl500618u ↗
40. Cancer-cell-membrane-Coated nanoparticles with a yolk-shell structure augment cancer chemotherapy10.1021/acs.nanolett.9b03817 ↗
41. Increasing the potential interacting area of nanomedicine enhances its homotypic cancer targeting efficacy10.1021/acsnano.9b08798 ↗
42. Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis10.1016/j.actbio.2021.03.056 ↗
43. Cell membrane camouflaged bismuth nanoparticles for targeted photothermal therapy of homotypic tumors10.1016/j.jcis.2021.02.006 ↗
44. The lysosome as a cellular centre for signalling, metabolism and quality control10.1038/s41556-018-0244-7 ↗
45. Autophagy at the crossroads of catabolism and anabolism10.1038/nrm4024 ↗
46. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype10.1038/s41467-018-03225-9 ↗
47. Oxidative stress and autophagy: the clash between damage and metabolic needs10.1038/cdd.2014.150 ↗
48. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-110.1002/advs.202002147 ↗
49. Endoplasmic reticulum stress-mediated membrane expression of CRT/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells10.18632/oncotarget.17678 ↗
50. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity10.1038/s41568-024-00674-x ↗
51. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway10.1158/1078-0432.CCR-09-2891 ↗
52. Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment10.2967/jnumed.120.245290 ↗
53. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death10.1136/jitc-2019-000337 ↗
54. Detection of immunogenic cell death and its relevance for cancer therapy10.1038/s41419-020-03221-2 ↗
55. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
56. Trial Watch: immunogenic cell death inducers for anticancer chemotherapy10.1080/2162402X.2015.1008866 ↗
57. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
58. Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity10.1016/j.isci.2021.102424 ↗
59. Immunogenic cell death inducer peptides: a new approach for cancer therapy, current status and future perspectives10.1016/j.biopha.2023.114503 ↗
60. Intelligent MoS(2)-CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/chemodynamic therapy/immunotherapy10.1016/j.biomaterials.2020.120545 ↗
61. Cell-penetrating nanoparticles activate the inflammasome to enhance antibody production by targeting microtubule-associated protein 1-light chain 3 for degradation10.1021/acsnano.0c00962 ↗
62. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance10.1016/j.immuni.2013.09.014 ↗
63. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens10.2147/IJN.S125866 ↗
64. Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses10.1016/j.ceb.2015.05.003 ↗
65. Lymph node stromal cells support the maturation of pre-DCs into cDC-like cells via colony-stimulating factor 110.1111/imm.13497 ↗
66. The roles of CD8(+) T cell subsets in antitumor immunity10.1016/j.tcb.2020.06.003 ↗
67. Identification and comprehensive Co-detection of necrotic and viable aneuploid cancer cells in peripheral blood10.3390/cancers13205108 ↗